title: Treatment of BRAF inhibitor-induced hyperkeratosis.
authors.forename: Jodie E
authors.initials: JE
authors.lastname: Battley
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Lenihan
authors.forename: Henry P
authors.initials: HP
authors.lastname: Redmond
authors.forename: Michelle
authors.initials: M
authors.lastname: Murphy
authors.forename: Derek G
authors.initials: DG
authors.lastname: Power
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002990:Clobetasol / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use; D007645:Keratoderma, Palmoplantar / Q000139:chemically induced* / Q000628:therapy*; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D010091:Oximes / Q000009:adverse effects / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D007093:Imidazoles; D010091:Oximes; D047428:Protein Kinase Inhibitors; D002990:Clobetasol; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib